Analysts Offer Insights on Healthcare Companies: Hologic (HOLX) and Myovant Sciences (MYOV)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Hologic (HOLXResearch Report) and Myovant Sciences (MYOVResearch Report).

Hologic (HOLX)

According to TipRanks.com, Kumar is a 3-star analyst with an average return of 2.8% and a 56.9% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Zimmer Biomet Holdings, and Baxter International.

Currently, the analyst consensus on Hologic is a Hold with an average price target of $74.67, representing a 6.0% upside. In a report issued on July 18, BTIG also downgraded the stock to Hold.

See Insiders’ Hot Stocks on TipRanks >>

Myovant Sciences (MYOV)

In a report issued on July 27, Joshua Schimmer from Evercore ISI maintained a Buy rating on Myovant Sciences, with a price target of $25.00. The company’s shares closed last Thursday at $13.21.

According to TipRanks.com, Schimmer is a 4-star analyst with an average return of 5.4% and a 48.7% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Aeglea Biotherapeutics, and Talaris Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Myovant Sciences with a $16.75 average price target, representing a 31.1% upside. In a report released yesterday, Robert W. Baird also maintained a Buy rating on the stock with a $20.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on HOLX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More